why choose us

First received: September 22, 2022

Clinical Trial: Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane Treatment, A ComboMATCH Treatment Trial

Study Status: Completed

Recruit Status: RECRUITING

Condition: Metastatic Malignant Solid Neoplasm

Study Type: INTERVENTIONAL


Official Title: Nilotinib and Paclitaxel in Patients With Prior Taxane-Treated Solid Tumors: A ComboMATCH Treatment Trial

Brief Summary: This phase II ComboMATCH treatment trial evaluates nilotinib with paclitaxel for the treatment of patients with solid cancers that are growing, spreading, or getting worse (progressive) and that have previously been treated with taxane therapies.Nilotinib is in a class of medications called kinase inhibitors.It works by binding to and blocking the action of a protein called ABL, which signals tumor cells to multiply.This helps slow or stop the proliferation of tumor cells.Paclitaxel is a drug that blocks cell…

Read more